Send me real-time posts from this site at my email
Motley Fool

Why INmune Bio Stock Soared Then Sank Today

What happened

Shares of INmune Bio (NASDAQ: INMB) soared as much as 19.4% in early trading on Thursday. However, the stock quickly gave up those gains and then some. INmune's shares were sinking 17% as of 3:39 p.m. EST.

The big jump came after the biotech announced encouraging results from a phase 1b study evaluating XPro1595 in treating Alzheimer's disease. However, the stock promptly fell throughout the morning -- probably due in part to profit-taking. Some investors were likely wary about banking too much on success for XPro1595 in light of the numerous Alzheimer's disease candidates that once seemed promising but ultimately flopped.

Image source: Getty Images.

So what

It's not all that surprising to see such high volatility for a clinical-stage biotech stock. Even good news can sometimes fail to keep investors excited for very long.

INmune's results did seem to be pretty good, though. The company reported that data from the phase 1b study suggested that patients who received XPro1595 experienced decreasing biomarkers of neuroinflammation based on several measures and assays. INmune's head of neurosciences, C.J. Barnum, said that this improvement in biomarkers "gives us great confidence that XPro1595 is having the desired effect in the CNS [central nervous system]."

However, these results are still very early. INmune still hasn't conclusively established that XPro1595 improves the condition of patients with Alzheimer's disease. More testing will be required.

Now what

INmune plans to move forward to conduct the additional testing that's needed. CEO RJ Tesi stated that the biotech intends to initiate a phase 2 clinical study of XPro1595 this year. The results from the phase 1b study will assist INmune in finalizing the design for the phase 2 study.

10 stocks we like better than INmune Bio, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and INmune Bio, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue